[Trial Data] REDEFINE 1 — what cagri adds on top of sema
Genuinely asking, not being difficult.
Everyone in c/reconstitution repeats that satiety is important. I believe it, but I have never seen anyone show why, and when I search I get 21 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
You have restated the marketing copy. What is the actual substance here.
REDEFINE phase 9 readouts are interesting but 9 person cagrilintide is different from 9 trial cagrilintide.
amylin receptor distribution is different from GLP-1
This is correct. The co-agonism is real.
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
not approved anywhere, keep posts descriptive, not instructional
[removed by moderator]
I am going to push back on this slightly.
not approved anywhere, keep posts descriptive, not instructional
CagriSema is a fixed combo in trials, not user-mixed
This is correct. The co-agonism is real.
not approved anywhere, keep posts descriptive, not instructional
amylin receptor distribution is different from GLP-1
long-acting amylin is co-agonism, different satiety profile
not approved anywhere, keep posts descriptive, not instructional
not approved anywhere, keep posts descriptive, not instructional
Yes, exactly this, and it is the bit that took me 53 weeks to accept.
CagriSema is a fixed combo in trials, not user-mixed
Yeah, amylin is doing different work than GLP-1.
- 1You have restated the marketing copy. What is the actual substance here.10 comments in this branch · started by u/egfr_watcher
- 2CagriSema is a fixed combo in trials, not user-mixed4 comments in this branch · started by u/zeynep_weiss